Literature DB >> 30201599

Pediatric Deep Venous Thrombosis and Pulmonary Embolism: Can It Be Antiphospholipid Syndrome?

Fatma Demir Yenigürbüz1, Hale Ören1.   

Abstract

Entities:  

Keywords:  Deep venous thrombosis; Pulmonary embolism; Antiphospholipid syndrome

Mesh:

Year:  2018        PMID: 30201599      PMCID: PMC6682786          DOI: 10.4274/tjh.galenos.2018.2018.0214

Source DB:  PubMed          Journal:  Turk J Haematol        ISSN: 1300-7777            Impact factor:   1.831


× No keyword cloud information.

To the Editor,

In pediatric patients with deep venous thrombosis (DVT) and pulmonary embolism (PE), antiphospholipid syndrome (APS) should be considered early and efforts must be made to ensure timely diagnosis of this potentially life-threatening condition. Pediatric APS is an autoimmune disease characterized by vascular thrombosis and persistently positive antiphospholipid antibodies [1,2,3,4,5]. Primary APS is rarely seen in childhood [4]. A 14-year-old adolescent was admitted with complaints of left upper leg edema for 1 week. On physical examination, obesity, hypertension, and edema of the leg were present. Hyperlipidemia and D-dimer elevation were remarkable. Doppler ultrasonography showed DVT in his left femoral vein and abdominal computed tomography (CT) demonstrated iliac vein thrombosis (Figure 1). Since he had widespread DVT, thorax CT angiography was also performed without any clinical symptoms of PE and it demonstrated filling defects in the right pulmonary artery (Figure 2). Anticoagulation was given and complete recanalization was observed. A diet program was started. When thrombophilia risk factors were evaluated, there was no family history and the genetic thrombophilia panel was negative, LA was positive twice with an interval of 12 weeks (first sample was before treatment), and other APS antibodies were found negative. Systemic lupus erythematosus (SLE) and SLE-like diseases were excluded. The patient was diagnosed with primary APS. Metabolic syndrome was the additional thrombotic risk factor. Long-term anticoagulation therapy (lifetime) was given to the patient.
Figure 1

Abdominal computed tomography of the patient demonstrating iliac vein thrombosis (arrows).

Figure 2

Thorax computed tomography angiography of the patient demonstrating filling defects in right pulmonary artery (arrows).

  5 in total

Review 1.  Pediatric antiphospholipid syndrome.

Authors:  Cassyanne L Aguiar; Arzu Soybilgic; Tadej Avcin; Barry L Myones
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

Review 2.  Diagnosis and treatment of antiphospholipid syndrome in childhood: A review.

Authors:  Dax G Rumsey; Barry Myones; Patti Massicotte
Journal:  Blood Cells Mol Dis       Date:  2017-02-28       Impact factor: 3.039

3.  Pulmonary embolism in childhood: how can we be sure not to miss it?

Authors:  Tina T Biss
Journal:  Arch Dis Child       Date:  2018-03-17       Impact factor: 3.791

Review 4.  European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative.

Authors:  Noortje Groot; Nienke de Graeff; Tadej Avcin; Brigitte Bader-Meunier; Pavla Dolezalova; Brian Feldman; Gili Kenet; Isabelle Koné-Paut; Pekka Lahdenne; Stephen D Marks; Liza McCann; Clarissa A Pilkington; Angelo Ravelli; Annet van Royen-Kerkhof; Yosef Uziel; Sebastiaan J Vastert; Nico M Wulffraat; Seza Ozen; Paul Brogan; Sylvia Kamphuis; Michael W Beresford
Journal:  Ann Rheum Dis       Date:  2017-05-04       Impact factor: 19.103

Review 5.  Pediatric thrombophilia.

Authors:  Janet Y K Yang; Anthony K C Chan
Journal:  Pediatr Clin North Am       Date:  2013-12       Impact factor: 3.278

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.